Zykadia (ceritinib) / Novartis 
Welcome,         Profile    Billing    Logout  
 20 Diseases   19 Trials   19 Trials   1670 News 


«12345678910111213...1819»
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Journal:  Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. (Pubmed Central) -  Nov 29, 2021   
    Among these, eltrombopag showed the highest potency against not only a drug-sensitive S. aureus strain but also 55 clinical isolates including 35 methicillin-resistant S. aureus (Minimum inhibitory concentration, MIC, to inhibit 50% growth [MIC] = 1.4-3.2 mg/L). Furthermore, we showed that eltrombopag inhibited bacterial growth in a cell infection model and reduced bacterial loads in infected mice, demonstrating its potential as a new antibiotic agent against S. aureus that can overcome current antibiotic resistance.
  • ||||||||||  Enrollment open, Metastases:  MatchMel: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (clinicaltrials.gov) -  Nov 24, 2021   
    P2,  N=1000, Recruiting, 
    Furthermore, we showed that eltrombopag inhibited bacterial growth in a cell infection model and reduced bacterial loads in infected mice, demonstrating its potential as a new antibiotic agent against S. aureus that can overcome current antibiotic resistance. Not yet recruiting --> Recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors and Chemotherapy (Pubmed Central) -  Nov 17, 2021   
    At the same time, the treatment showed common adverse reactions of ALK inhibitors. This paper analyzed the therapeutic effect and treatment dilemma of this patient, and provided an exploration direction for the treatment of patients with EML4-ALK fusion gene positive lung cancer..
  • ||||||||||  nintedanib / Generic mfg.
    Journal, Harmonization:  A multi-modal data harmonisation approach for discovery of COVID-19 drug targets. (Pubmed Central) -  Nov 17, 2021   
    Strongly correlated features within each of these two datasets were used for drug-target analysis, resulting in a list of 84 drug-target candidates. Further computational docking and toxicity analyses revealed seven high-confidence targets, amsacrine, bosutinib, ceritinib, crizotinib, nintedanib and sunitinib as potential starting points for drug therapy and development.
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
    Journal:  Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. (Pubmed Central) -  Oct 28, 2021   
    Further flow cytometric analysis indicated that 10f could effectively induce cell death via cell apoptosis and cell cycle arrest. Taken together, these results suggested 10f would be a promising lead compound for the ALK-positive NSCLC treatment, especially the Ceritinib- or Crizotinib-resistant NSCLC.
  • ||||||||||  YHO-1701 / Yakult Honsha
    Preclinical, Journal:  Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines. (Pubmed Central) -  Oct 27, 2021   
    The combination of YHO-1701 with alectinib resulted in significantly greater antitumor activity without exhibiting body weight loss in an NCI-H2228 [echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion] xenograft mouse model. Our results strongly suggest that the logical strategy in combination with the novel STAT3 inhibitor YHO-1701 and other mechanistically different targeted agents, could be a promising approach in future clinical settings.
  • ||||||||||  Clinical, Review, Journal:  Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review). (Pubmed Central) -  Sep 1, 2021   
    A series of studies have indicated that ALK‑TKI agents as the first‑line treatment, including crizotinib, ceritinib, brigatinib, alectinib and entrectinib, can benefit patients with ALK‑positive NSCLC...This study reviews the pharmacodynamics, efficacy and safety of ALK‑TKI agents in order to summarize these effects as well as the relevant management strategies. It is worth emphasizing that the frequency and severity of an adverse effect often varies across different trials.
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Ceritinib (Twitter) -  Aug 27, 2021   
  • ||||||||||  [VIRTUAL] Systemic therapy first (Channel 2) -  Aug 20, 2021 - Abstract #EANO2021EANO_208;    
    Particularly in HER2 positive disease, certain agents (tucatinib, neratinib and ponatinib) have shown impressive efficacy in the central nervous system. In summary, several common solid tumors with a targetable mutation and CNS metastases can be approached pharmacologically in order to avoid or delay the use of radiotherapy and it's side effects.
  • ||||||||||  Zykadia (ceritinib) / Novartis, Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date:  NEPENTHE: Next Generation Personalized Neuroblastoma Therapy (clinicaltrials.gov) -  Aug 19, 2021   
    P1,  N=131, Recruiting, 
    In summary, several common solid tumors with a targetable mutation and CNS metastases can be approached pharmacologically in order to avoid or delay the use of radiotherapy and it's side effects. Trial completion date: May 2026 --> Jun 2024 | Trial primary completion date: Jul 2021 --> Jun 2023
  • ||||||||||  Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
    Trial completion date, Trial primary completion date:  Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (clinicaltrials.gov) -  Aug 18, 2021   
    P1,  N=27, Recruiting, 
    Trial completion date: May 2026 --> Jun 2024 | Trial primary completion date: Jul 2021 --> Jun 2023 Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2022
  • ||||||||||  [VIRTUAL] Real - World Clinically - Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC (ePoster Hall) -  Aug 9, 2021 - Abstract #IASLCWCLC2021IASLC_WCLC_1063;    
    Median overall survival (OS) in patients with at least one treatment modification trended, but was not significantly different from patients without any treatment modification (47.0 vs 57.8 months, p=0.09). Conclusion In a real-world cohort, treatment modifications on ALK-TKI were needed frequently, even with the newer generation of ALK-TKIs, highlighting the importance of availability of different ALK-TKIs for patients experiencing AEs to ensure tolerable targeted treatment.